



## **Araf51 with improved transglycosylation activities: One engineered biocatalyst for one specific acceptor**

Alizé Pennec, Richard Daniellou, Pascal Loyer, Caroline Nugier-Chauvin,  
Vincent Ferrières

### **► To cite this version:**

Alizé Pennec, Richard Daniellou, Pascal Loyer, Caroline Nugier-Chauvin, Vincent Ferrières. Araf51 with improved transglycosylation activities: One engineered biocatalyst for one specific acceptor. Carbohydrate Research, 2015, 402, pp.50-55. 10.1016/j.carres.2014.10.031 . hal-01086640

**HAL Id: hal-01086640**

**<https://hal-univ-rennes1.archives-ouvertes.fr/hal-01086640>**

Submitted on 24 Nov 2014

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

## **Araf51 with improved transglycosylation activities: One engineered biocatalyst for one specific acceptor.**

Alizé Pennec,<sup>a,b</sup> Richard Daniellou,<sup>a,b,§</sup> Pascal Loyer,<sup>b,c</sup> Caroline Nugier-Chauvin\*,<sup>a,b</sup> Vincent Ferrières\*,<sup>a,b</sup>

<sup>a</sup> Ecole Nationale Supérieure de Chimie de Rennes, CNRS, UMR 6226, 11 Allée de Beaulieu, CS 50837, 35708 Rennes Cedex 7, France

<sup>b</sup> Université européenne de Bretagne, France

<sup>c</sup> INSERM UMR 991, Hôpital Pontchaillou, 35033 Rennes Cedex, France

**Abstract:** A random mutagenesis of the arabinofuranosyl hydrolase Araf51 has been run in order to access to efficient biocatalysts for the synthesis of alkyl arabinofuranosides. The mutants were selected on their ability to catalyze the transglycosylation reaction of *p*-nitrophenyl  $\alpha$ -L-arabinofuranoside (*p*NP-Araf) used as a donor and various aliphatic alcohols as acceptors. This screening strategy underlined 5 interesting clones, each one corresponding to one acceptor. They appeared to be much more efficient in the transglycosylation reaction compared to the wild type enzyme whereas no self-condensation or hydrolysis products could be detected. Moreover, the high specificity of the mutants towards the alcohols for which they have been selected validates the screening process. Sequence analysis of the mutated enzymes revealed that, despite their location far from the active site, the mutations affect significantly

\*Corresponding author at: Ecole Nationale Supérieure de Chimie de Rennes, CNRS, UMR 6226, 11 Allée de Beaulieu, CS 50837, 35708 Rennes Cedex 7, France. Tel.: 33(0)2 23238066. Email address: caroline.nugier@ensc-rennes.fr

§ Present address: Institut de Chimie Organique et Analytique (ICOA), UMR CNRS 7311, Université d'Orléans, BP 6759, Rue de Chartres, 45067 Orléans Cedex 2, France

the kinetics properties as well as the substrate affinity of these mutants towards the alcohol acceptors in the transglycosylation reaction.


**Keywords:** Furanosides, Transglycosylation, Random mutagenesis, Furanosidase

## 1. Introduction

One of the current needs in chemical research is the development of greener and more eco-friendly reactions. The glycosylation is an example thereof, being one of the most important and difficult reactions for biomolecules synthesis. Indeed, it still remains a challenge in chemistry requiring multiple reaction steps and the use of various protecting groups. In Nature there are multiple enzymes as glycosyltransferases, polysaccharide lyases and glycosidases able to assemble or cleave easily the glycosidic bond with high regioselectivity.<sup>1</sup> Nowadays, biotechnological approaches are recognized as powerful tools for the synthesis of glycoconjugates and improving biocatalyst efficiency seems to be one of the most promising approaches.<sup>2-7</sup> Moreover it is noteworthy that the chemical synthesis of arabinofuranosides with a high degree of stereocontrol and without any pyranosidic forms, suffers from a lack of generality. For instance the synthesis of alkyl arabinofuranosides is generally obtained from the key intermediates per-*O*-protected furanoses.<sup>8-10</sup> However, biocatalyzed furanosylation has been recently developed and its versatility was further extended to the preparation of non-natural furanosyl-containing conjugates (for a review, see reference<sup>11</sup>). Indeed, glycosidases are good candidates in comparison to other enzymes, thanks to their stability, ease of production and low-cost of substrates which can be bio-sources. A recent example of directed evolution was applied to the  $\beta$ -glycosidase of *Thermus thermophilus* in order to increase its ability to synthesize oligopyranosides vs. its hydrolytic activity.<sup>12-14</sup> To achieve these results, Koné et al. developed a high-throughput digital imaging screening methodology to detect transglycosidase mutants in *E. coli* cells.<sup>14</sup>

Herein, we adapted and completed this kind of screening to improve arabinofuranosyl transglycosylation with the aim to apply it to a wide range of aliphatic alcohols (Scheme 1). As a model reaction, we chose to synthesize alkyl  $\alpha$ -L-arabinofuranosides which are simple molecules with diverse properties and potential uses. Depending on the nature of the alkyl chain, they find

applications as immunostimulating agents or antiparasitic drugs.<sup>15-17</sup> More generally, the alkyl pyranosidic counterparts act as chemical building blocks for further derivatization and industrial preparation of alkyl polyglycosides.<sup>18,19</sup>



**Scheme 1.** Enzymatic synthesis of alkyl  $\alpha$ -L-arabinofuranosides.

In this context, we performed random mutagenesis on the  $\alpha$ -L-arabinofuranosidase (Ara<sub>f</sub>51) from *Clostridium thermocellum* in an attempt to improve the transglycosylation activities for the synthesis of alkyl  $\alpha$ -L-arabinofuranosides. For the selection of suitable variants, a screening in two steps has been developed. The initial one, directly on plates, allowed colony selection of mutants with good hydrolytic activity on an Ara<sub>f</sub>-containing chromogenic substrate. Indeed in order to maintain the physical quality of the agar gels and cells viability, the presence of alcohols as acceptors was excluded for this first screening step. The second one assessed the transglycosylation activities towards the convenient alcohol acceptor of the previous selected enzymes by 96-well spectrophotometry. In this approach, one of the main objectives was to obtain mutants with high selectivity towards nucleophilic alcohols: one specific mutant for one specific acceptor.

## 2. Results and discussion


### 2.1. Identification of mutants with improved transglycosylation abilities.

The thermostable arabinofuranosyl hydrolase, Ara51, naturally removes  $\alpha$ -(1 $\rightarrow$ 2),  $\alpha$ -(1 $\rightarrow$ 3) and  $\alpha$ -(1 $\rightarrow$ 5)-linked L-arabinofuranosyl units from arabinans and arabinoxylans. To the best of our knowledge, this enzyme belongs to the only arabinofuranosidase family (GH51) showing the ability to catalyze transglycosylation reactions. In addition, Ara51 has been described several times for its substrate versatility as it recognizes arabinofuranosides as well as galactofuranosides.<sup>17,20-23</sup> Preliminary experiments showed the ability of the Ara51 wild type (wt) to transglycosylate *p*NP-Ara5 to small aliphatic alcohol in order to obtain alkyl  $\alpha$ -L-arabinofuranosides.<sup>24</sup> However, the activity strongly decreased when acceptors contain more than 3 carbons in their chain. With the aim to improve the transglycosylation activity towards aliphatic alcohols, mutants were thus created by random mutagenesis and selected from a simple screening procedure.

Firstly, a library of mutated Ara51 genes has been generated by error prone PCR and cloned into pCR® 2.1-TOPO® vector. After cell transformations, *E. coli* BL21 DE3 clones were spread on LB plates for the screening. This latter consisted in a first selection of positive colonies overexpressing an active Ara51. During this step, the colonies were plated on LB media containing IPTG and 1.5 mM of 5-bromo-indolyl  $\alpha$ -L-arabinofuranosyl.<sup>25</sup> This molecule is hydrolyzed by the Ara51 releasing a blue air-oxidized di-indolyl compound. In this way, the colonies staining in blue expressed enzymes successfully cloned which still recognize the arabinofuranosyl moiety as donor. Ideally, mutants that tend to favor transglycosylation were supposed to perform slow aglycon release in the absence of a suitable acceptor and therefore display a pale blue staining. Nevertheless, a low expression level of some mutated enzymes could also result in a pale coloration. Also, the selection of all the blue colonies was performed and the transglycosylation properties of the resulting enzymes assayed.

This first step allowed us to select more than 120 colonies for further expression of the mutated enzymes. The corresponding cell free extracts were heated at 70 °C to remove most of the *E. coli* derived proteins and also confirmed the thermostability of the selected mutants. In the second step of

the screening procedure, each enzyme was tested in the presence of *p*NP-Araf and an alcohol in order to evaluate their transglycosylation ability (T) over hydrolysis potential (H) (Scheme 2). UV-measurements were performed during the initial time where the deglycosylation of the glycosyl-enzyme intermediate is the rate-limiting step. If the transglycosylation is favored, the initial speed rate in these conditions should be higher than the one during the hydrolysis. The initial reaction rates were determined thanks to the release of *p*-nitrophenol (405 nm). For each cell free extract, two types of reaction were performed, in presence and absence of alcohol acceptor. The alcohol volume was up to 25% (v/v) to limit the presence of water, and so to favor as much as possible the target transglycosylation. DMSO was added to the reaction mixture as an optimized solubility factor for aliphatic alcohol. Reactions were performed at pH 8 to ensure maintaining the phenolate form of the leaving group and thus proper UV-visible monitoring. A range of linear alcohols were tested from methanol to *n*-hexanol as well as *i*-propanol, allylic alcohol and solketal.



**Scheme 2.** Araf51-catalyzed transglycosylation with *p*NP-Araf as donor and alcohols as acceptors.

To easily reveal interesting enzymes, the initial speed rates obtained ( $V_i$ ) were normalized with the one corresponding to the wild type. Then, a ratio  $R$  was calculated correlating directly to the increase of activity in presence of the acceptor (Equation 1).

$$R = \frac{V_i \text{ H+T}}{V_i \text{ H}} \quad (\text{Equation 1})$$

with  $V_{i_{H+T}}$  corresponds to the initial rate in presence of alcohol, and  $V_{i_H}$  to the initial rate without alcohol.

For each alcohol tested, around twenty mutants showed positive activation with R value above 1. In order to detect these mutants with potentially better transglycosylation than the wild type, analytic time course reactions were performed and conversions (Table 1) determined by NMR spectroscopy: the protons corresponding to the *p*NP group are up-field shifted when released, and the appearance of a new anomeric proton from the product was clearly observed (see supplementary materials). On this basis, we focused our attention on five mutants. Then preparative reactions were performed, and the transglycosylation products were isolated by column chromatography (Table 1). The alkyl resulting  $\alpha$ -L-arabinofuranosides were characterized by  $^1\text{H}$  and  $^{13}\text{C}$  NMR analysis. These data were in accordance with previously recorded results for compounds **1-5**, **9**<sup>26-28</sup> and new furanosides **6-8** were fully described in the experimental part.


**Table 1.** Conversions and yields by transglycosylation using Ara/51 wt and selected mutants for different alcohol acceptors.

Entry	Acceptor	Ara/51 wt		Mutant			Improvement <sup>c</sup>
		Conversion <sup>a</sup> (%)	Time (min)	Conversion <sup>a</sup> (%)	Time (min)	Yield <sup>b</sup> (%)	
1	MeOH	95	60	-	-	-	
2	EtOH	90	60	-	-	-	
3	<i>n</i> -PrOH	85	120	96 (M20)	60	60	+ 13%
4	<i>i</i> -PrOH	30	120	38 (M22)	60	30	+ 27%
5	Solketal	38	120	-	-	-	
6	AlLOH	76	120	-	-	-	
7	<i>n</i> -BuOH	42	50	92 (M12)	20	68	+ 119%
8	<i>n</i> -PentOH	72	120	96 (M60)	120	80	+ 33%

9	<i>n</i> -HexOH	37	120	94 (M57)	120	71	+ 154%
---	-----------------	----	-----	----------	-----	----	--------

<sup>a</sup>Conversion in transglycosylated product; <sup>b</sup>Isolated yield; <sup>c</sup>Was obtained as 100x(Conversion mutant – Conversion wt)/Conversion wt.

Data from Table 1 firstly showed that moderate (*i*-propanol, solketal, *n*-butanol, *n*-hexanol) to excellent (methanol, ethanol) conversions in transglycosylated derivatives were generally obtained using the wild type biocatalyst but long reaction times were required (up to 2 hours). Secondly, it is important to note that no autocondensation product has been observed, probably due to the high concentration of alcohol acceptor that favored the desired transglycosylation. Subsequently, the mutation procedure of Ara/51 wt enabled the isolation of 5 mutants with significant improved transglycosylation activities for *n*- propanol, *i*- propanol, *n*- butanol, *n*-pentanol, and *n*- hexanol (entries 3, 4, 7, 8, 9, respectively). In comparison to the native enzyme, the engineered biocatalysts were all more promising in term of reaction time and conversion in transglycosylation, with improvement from + 13% for M20 (*n*-propanol, entry 3) to + 154% for M57 (*n*- hexanol, entry 9). As an example, time course evolution between the wild type biocatalyst and the M20 mutant was given in figure 1. Unfortunately, the proposed protocol did not afford improved biocatalyst for solketal and allyl alcohol. Nevertheless, under the transglycosylation conditions performed with the selected mutants, hydrolysis of the resulted arabinofuranosides was not observed, even over 120 minutes and after total consumption of the substrate. Finally, no other transglycosylation by-products (autocondensation) were observed, so that the targeted  $\alpha$ -L-arabinofuranosides were specifically formed, confirming the diastereoselectivity of the mutants according to the glycosidic bond, whatever the nature of the biocatalyst.





**Figure 1.** Time course of transglycosylation into propyl  $\alpha$ -L-arabinofuranoside (black) from *p*NP-Araf (grey) by **a)** Araf51 wt and **b)** M20.

In order to evaluate the selectivity towards the aliphatic acceptor thanks to the mutated biocatalysts, transglycosylation reactions were performed with other structurally close alcohols (Table 2). It appeared that the mutants showed significantly better transglycosylation ability for the alcohol for which they were selected than for other acceptors. For instance, M20 mutant was particularly efficient and selective for *n*-propanol.

**Table 2.** Selectivity of the mutated enzymes (% of transglycosylation conversion).

Entry	Mutant	EtOH	<i>n</i> -PrOH	<i>i</i> -PrOH	<i>n</i> -BuOH	<i>n</i> -PentOH	<i>n</i> -HexOH
1	M20	20	<b>96</b>	4	10		
2	M22		26	<b>38</b>	25		
3	M12		19		<b>92</b>	35	
4	M60				65	<b>96</b>	79
5	M57					65	<b>94</b>

## 2.2. Kinetic characterization and mutation identification of the selected enzymes

Finally, the kinetic parameters of the different mutants were determined under hydrolysis conditions of *p*NP-Araf at 25 °C and pH 8 (50 mM Tris HCl buffer). Whereas Araf 51 is a thermophilic enzyme with  $T_{opt}$  around 82 °C, the parameters were determined at 25 °C for practical reasons, as previously reported.<sup>29</sup> The data presented in table 3 compares the values obtained with the Araf51 wt to the ones calculated for the selected enzymes. Most of the new biocatalysts showed lower  $K_m$  by comparison with the wild type, especially for M20 and M22. Furthermore,  $k_{cat}$  values for the mutants were also lower than that for the wild type Araf51.

**Table 3.** Determination of Araf51 wt and selected mutants kinetic parameters for the hydrolysis reaction of *p*NP-Araf (pH 8, 50 mM of Tris HCl buffer, at 25 °C).

Enzyme	$K_m$ (mM)	$k_{cat}$ ( $s^{-1}$ )	$k_{cat}/K_m$
Ara51 wt	$0.34 \pm 0.08$	$143 \pm 5$	420
M20	$0.07 \pm 0.02$	$133 \pm 6.4$	1900
M22	$0.07 \pm 0.01$	$20.9 \pm 1.2$	298
M12	$0.26 \pm 0.10$	$93.8 \pm 12$	360
M60	$0.17 \pm 0.06$	$118 \pm 8.7$	694
M57	$0.16 \pm 0.04$	$73.6 \pm 4.7$	460

On a structural point of view, the crystal structure of the wild type enzyme has been previously solved (PDB file: 2C7F) and showed that two essential catalytic residues are required for the hydrolysis reaction were assigned as the acid/base residue Glu173 and the nucleophile Glu292. Moreover, structural information was also obtained from the co-crystallised of the inactive mutant E173A form of Ara51 with natural arabinotriose and arabinoxylobiose.<sup>29</sup> These studies suggest little specificity for the exact orientation of the aglycone in the +1 subsite due to flexible conformation adopted by Trp178 which stacks against the aglycone sugar unit. The sequence analysis of the mutants from this study revealed from one to six mutations (Table 4, see also supplementary data). It clearly appeared that the mutations were neither within the active site nor close to it. Nevertheless, concerning the biocatalyzed synthesis of the target alkyl arabinofuranosides, we expected that the alkyl chains could fit the entry of the common GH51 ( $\beta/\alpha$ )<sub>8</sub> barrel domain located at the extremity of the -1 subsite. Despite the location of the mutated sites, far from the active site, these mutations seemed to significantly affect the kinetics properties with regards to substrate affinity and transglycosylation reaction activity.

**Table 4.** Identified mutations.

Enzyme	Mutations
M20	R51G, V105L, T220S, S268T, A348S
M22	P392S
M12	K115T

M60 V105L, D134G, T220S, S268T, A348S, E405D

M57 V105L, T220S, S268T

### 3. Conclusion

Thanks to the coupling of random mutagenesis method conducted on the arabinofuranosyl hydrolase Ara<sub>f</sub>51 and an efficient screening, we have obtained five mutants able to catalyze the transfer of an arabinofuranosyl entity to various aliphatic alcohols. In comparison to the wild type enzyme, these new biocatalysts improved the transglycosylation conversions up to 96%. Additionally, the procedure used in the study yielded new biocatalysts with increased transglycosylation abilities and selectivity closely depending on the nature of the acceptor for which they were screened. This strategy was efficient with the aim of synthesizing valuable chemical building blocks such as alkyl  $\alpha$ -L-arabinofuranosides. Additional benefits mutations in these rationally designed enzymes appeared to be distant from the active site. Further directed evolution experiments targeted on these observed mutations are now required in order to study the properties and catalytic abilities of the generated enzymes and to accurately understand the involvement of each modified site.

### 4. Experimental

#### 4.1. Expression and purification of Ara<sub>f</sub>51 and mutant derivatives

Plasmid pET28a (+) (Novagen) containing Ara<sub>f</sub>51 wild type from *Clostridium thermocellum*<sup>29</sup> and kanamycin resistance genes was provided by Prof G. Davies, University of York, U. K. Plasmid pCR®2.1-TOPO® (3.9 kb) from Invitrogen contains encoding mutated enzymes genes as well as ampicillin and kanamycin resistance genes. These plasmids were under the control of T7 promoter.

The enzymes were produced in *Escherichia coli* BL21 DE3 cells (Invitrogen) cultured in LB (Lysogeny broth) plates containing 0.1 mM of the corresponding selective agent at 37 °C. 10 millilitres of LB medium supplemented with antibiotic were inoculated with one single positive colony *E. coli* BL21 (DE3) and incubated overnight at 37 °C, 250 rpm. That was subsequently used to prepare 1% inoculum (200 mL LB + antibiotic, 250 rpm, 37 °C). Cells were grown to mid-exponential phase [Absorbance, A<sub>550</sub>: 0.7] at which point *i*-propyl  $\beta$ -D-thiogalactopyraoside (IPTG) was added to a final

concentration of 1.0 mM and the cultures were incubated for 14 h at 37 °C. After centrifugation (20 min, 4000 rpm, 4 °C), the cells were resuspended in 50 mM Tris HCl buffer pH 8 and sonicated (3 × 10 s) for another centrifugation (30 min, 20000 rpm, 4 °C), the supernatant was heated at 70 °C for 15 min to remove a major amount of proteins and centrifuged again at 20000 rpm for 30 min. Protein concentrations were determined by the Bradford method.<sup>30</sup> The purity of His-tagged Ara51 was confirmed by SDS-PAGE after Ni-NTA agarose affinity chromatography (Novagen, USA).

#### 4.2. Determination of Ara51 kinetic parameters

The kinetic parameters  $K_m$  and  $k_{cat}$  of Ara51 were quantified in triplicate by incubation of the enzyme (10 µL of ≈ 1 mg/mL) with different concentrations of *p*-nitrophenyl α-L-arabinofuranoside (6 to 0.02 mM) in 50 mM Tris HCl buffer pH 8 at 25 °C. The release of *p*-nitrophenol was measured at 405 nm during 5 min (Microplates Spectrophotometer PowerWave XS/XS2, BioTek). The kinetic parameters were determined by calculations using GOSA software with repeatability.

#### 4.3. Random mutagenesis

Random mutagenesis was performed by GeneMorph II Random Mutagenesis kit (Stratagene) using mutagenic PCR. The open reading frame encoding Ara51 was amplified using the primers:

- forward T7 Promoter TACGACTCACTATAGGGGAA and reverse T7 Promoter GCTAGTTATTGCTCAGCGGT (Strategy 1);
- forward T7 Promoter TACGACTCACTATAGGGGAA and reverse T7 Promoter GTGAGTCGTATTAATTTTCGCGGT (Strategy 2).

For low mutation number (mutation frequency 0 – 4.5 mutations / kb), 500 ng of the initial target DNA were mixed with 250 ng of each primer, 1 µL of 40 mM dNTP mix (final concentration of 800 µM each), 5 µL of 10 × Mutazyme II reaction buffer and 1 µL of Mutazyme II DNA polymerase (2.5 U/µL) completed to 50 µL with H<sub>2</sub>O. The reaction was thermocycled as follows: one hot start cycle (95 °C, 2 min) then 10 cycles: first the denaturing step (95 °C, 30 s), the hybridization step (60 °C, 30 s) and the elongation step performed for 1min/kb (72 °C, 7 min or 10 min); and finally one cycle at 72 °C for 10 min. Only for the second strategy, mutagenesis PCR products were directly cloned into a

plasmid vector using the TOPO TA Cloning® Invitrogen protocol. The fresh PCR product (2 µL) was mixed with the different reagents provided in the TOPO TA Cloning® Invitrogen kit: 1 µL salt solution, 1 µL pCR®2.1-TOPO® vector and H<sub>2</sub>O was added up to a final volume of 6 µL. The reaction was incubated for 5 min at room temperature (22-23 °C).

#### 4.4. Screening of mutants

The blue colonies were selected and cultivated in 5 mL LB media containing 0.1 mM kanamycin LB media. The enzymes were purified as previously described and analyzed for their transglycosylation activities. As previously, protein concentration was estimated by Bradford method. Enzyme assays were performed to compare transglycosylation activities (presence of the alcohol acceptor) to hydrolytic activities (absence of the alcohol). Mutants and Ara/51 wt enzymes were incubated in pH 8 Tris HCl 50 mM buffer with 20 mM *p*NP-Araf, 20% (v/v) DMSO, with or without 25% (v/v) alcohol for a final volume of 140 µL at 50 °C. The final concentration in enzyme necessarily reached 0.017 mg/mL, thus the collected volume having to be adapted to each attempt following the determination of the initial concentration by the Bradford method. The release of *p*-nitrophenol was measured at 405 nm during 5 min (Microplate Spectrophotometer Powerwase XS/XS2, Biotek) and data evaluated with Gen5 Data Analysis Software (Biotek). The initial activities of the enzyme and mutated enzymes were determined using the monitoring of UV curves of the enzymatic assays. This enabled to compare the slope between Ara/51 wt and the one of the mutants with or without the presence of alcohol acceptors, and highlighted the mutants of interest. Indeed, the mutated enzymes presenting a higher slope than the one of the Ara/51 wt, in presence of alcohol, showed higher reaction activations, meaning that transglycosylation was preferred.

#### 4.5. Analytical scale of transglycosylation reactions, NMR kinetics

Enzymatic reactions were run from 20 mM *p*NP-Araf (4.3 mg) and 200 µL of alcohol acceptor incubated in pH 8 Tris HCl 50 mM buffer with 160 µL of DMSO. The enzyme preparation was added (a final concentration of 0.017 mg/mL is required) to the solution, and finally completed to a final volume of 800 µL and maintained at 50 °C during 3 h. Aliquots (100 µL) of the enzymatic reaction

mixture were withdrawn at several times and directly freeze with liquid nitrogen. After complete lyophilization, samples were solubilized in 500  $\mu$ L of  $CD_3OD$  to enable the analysis by NMR. Transglycosylation activities using *p*NP-Araf as glycosyl donor were determined by  $^1H$  NMR. By monitoring the decrease of the *p*NP-Araf signal (aromatic protons  $\delta=8.21$  ppm and/or anomeric proton  $\delta=5.66$  ppm) and the release of *p*-nitrophenol (aromatic protons  $\delta=8.12$  ppm) corresponding to both the hydrolysis and the transglycosylation of the donor, the residual starting material can easily be quantified. The transglycosylation products were visualized by the emergence of the anomeric proton signal of the furanoside and/or the signal of the alkyl group protons. By reporting the relation between the proton signals, the resulting conversions were determined.

#### 4.6. General procedure for the synthesis of alkyl arabinofuranosides in a preparative scale

Experiments were performed in 50 mM Tris HCl buffer, pH 8 at 50 °C in the presence of *p*NP-Araf (30 mg, 0.11 mM), 1.4 mL of alcohol and 1.12 mL of DMSO in a total reaction volume of 5.6 mL. Araf51 wild type or mutated was added to a final concentration of 0.017 mg/mL and the reaction was performed at 50 °C during the optimal duration determined at the analytical scale experiment. Then the mixture was concentrated under reduced pressure and the reaction products were separated by column chromatography on silica gel (AcOEt/AcOH/H<sub>2</sub>O, 50:1:1) affording the desired product.

#### 4.7. Purification and analysis of synthetic alkyl arabinofuranosides

Thin layer chromatography (TLC) analysis were conducted on E. Merck 60 F<sub>254</sub> Silica Gel non activated plates and compounds were visualized by UV (254 nm), or a 5% solution of H<sub>2</sub>SO<sub>4</sub> solution in EtOH containing orcinol, followed by heating. For column chromatography, Si 60 (40-63  $\mu$ m) Silica Gel was used. NMR spectra were recorded on a Bruker spectrometer ARX (400 MHz for  $^1H$  and 100 MHz for  $^{13}C$ ). Chemical shifts are expressed in  $\delta$  units (ppm). Chemical shifts are calculated in Hertz and pattern abbreviations are as follows: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), dd (double doublet)...The HRMS were measured with a Micro-Tof-Q 2 (Bruker) equipped with electrospray and APCI ionization sources, two quadrupole-orthogonal accelerators and reflection

time-of-flight analyzer, or a Q-tof 2 (Waters) equipped with electrospray ionization source, two quadrupole-orthogonal accelerators and reflection time-of-flight analyzer.

#### 4.8. *n*-Pentyl $\alpha$ -L-arabinofuranoside (**6**)

*n*-Pentyl  $\alpha$ -L-arabinofuranoside **6** was obtained according to the described general procedure for transglycosylation by incubation of *n*-pentanol in the presence of the Ara51, and was isolated in 66% yield (16.1 mg) after purification by column chromatography.  $^1\text{H}$  NMR ( $\text{CD}_3\text{OD}$ ):  $\delta$  4.84 (d, 1H,  $J_{1,2} = 2.0$  Hz, H-1), 3.94 (dd, 1H,  $J_{2,3} = 4.0$  Hz, H-2), 3.92-3.89 (m, 1H, H-4), 3.82 (dd, 1H,  $J_{3,4} = 6.4$  Hz, H-3), 3.73 (dd, 1H,  $J_{4,5} = 3.2$  Hz,  $J_{5a,5b} = 12.0$  Hz, H-5a), 3.71 (dt, 1H,  $J_{\text{CH}_2, \text{CH}_2} = 10.0$  Hz,  $J_{\text{CH}_2, \text{CH}_2} = 6.4$  Hz,  $\text{OCH}_2\text{CH}_2$ ), 3.62 (dd, 1H,  $J_{4,5b} = 5.2$  Hz, H-5b), 3.41 (dt, 1H,  $J_{\text{CH}_2, \text{CH}_2} = 9.6$  Hz,  $J_{\text{CH}_2, \text{CH}_2} = 6.8$  Hz,  $\text{OCH}_2\text{CH}_2$ ), 1.61-1.57 (m, 2H,  $\text{OCH}_2\text{CH}_2$ ), 1.36-1.34 (m, 4H,  $\text{CH}_2\text{CH}_2\text{CH}_3$ ), 0.92 (t, 3H,  $J_{\text{CH}_2, \text{CH}_3} = 7.2$  Hz,  $\text{CH}_3$ ).  $^{13}\text{C}$  NMR ( $\text{CD}_3\text{OD}$ ):  $\delta$  109.4 (C-1), 85.1 (C-4), 83.6 (C-2), 78.7 (C-3), 68.8 ( $\text{OCH}_2\text{CH}_2$ ), 63.0 (C-5), 30.4 ( $\text{OCH}_2\text{CH}_2$ ), 29.5 ( $\text{CH}_2\text{CH}_2\text{CH}_3$ ), 23.5 ( $\text{CH}_2\text{CH}_3$ ), 14.4 ( $\text{CH}_3$ ). HRMS ( $\text{ESI}^+$ ):  $m/z$  calcd for  $\text{C}_{10}\text{H}_{20}\text{O}_5\text{Na}$   $[\text{M}+\text{Na}]^+$   $m/z$  243.1208 ; found,  $m/z$  243.1676.

#### 4.9. *n*-Hexyl $\alpha$ -L-arabinofuranoside (**7**)

*n*-Hexyl  $\alpha$ -L-arabinofuranoside **7** was obtained according to the described general procedure for transglycosylation by incubating *n*-hexanol in the presence of the Ara51 wt. It was isolated in 71% yield (18.5 mg) after purification by column chromatography.  $^1\text{H}$  NMR ( $\text{CD}_3\text{OD}$ ):  $\delta$  4.84 (d, 1H,  $J_{1,2} = 2.0$  Hz, H-1), 3.94 (dd, 1H,  $J_{2,3} = 4.0$  Hz, H-2), 3.92-3.90 (m, 1H, H-4), 3.82 (dd, 1H,  $J_{3,4} = 6.4$  Hz, H-3), 3.74 (dd, 1H,  $J_{4,5} = 3.2$  Hz,  $J_{5a,5b} = 12.0$  Hz, H-5a), 3.71 (dt, 1H,  $J_{\text{CH}_2, \text{CH}_2} = 6.8$  Hz,  $J_{\text{CH}_2, \text{CH}_2} = 9.6$  Hz,  $\text{OCH}_2\text{CH}_2$ ), 3.62 (dd, 1H,  $J_{4,5b} = 5.6$  Hz, H-5b), 3.41 (dt, 1H,  $J_{\text{CH}_2, \text{CH}_2} = 9.6$  Hz,  $J_{\text{CH}_2, \text{CH}_2} = 6.4$  Hz,  $\text{OCH}_2\text{CH}_2$ ), 1.60-1.57 (m, 2H,  $\text{OCH}_2\text{CH}_2$ ), 1.35-1.32 (m, 6H,  $\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$ ), 0.91 (t, 3H,  $J_{\text{CH}_2, \text{CH}_3} = 6.8$  Hz,  $\text{CH}_3$ ).  $^{13}\text{C}$

NMR (CD<sub>3</sub>OD):  $\delta$  109.4 (C-1), 85.1 (C-4), 83.6 (C-2), 78.7 (C-3), 68.8 (OCH<sub>2</sub>CH<sub>2</sub>), 63.0 (C-5), 32.8 (OCH<sub>2</sub>CH<sub>2</sub>), 30.7 (CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>), 26.9 (CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>), 23.7 (CH<sub>2</sub>CH<sub>3</sub>), 14.4 (CH<sub>3</sub>). HRMS (ESI<sup>+</sup>): calcd for C<sub>11</sub>H<sub>22</sub>O<sub>5</sub>Na [M+Na]<sup>+</sup> m/z 257.1365; found, m/z 257.1915.

#### 4.10. 3-O- $\alpha$ -L-arabinofuranosyl-O-isopropylidene-sn-glycerol (**8**)

The desired furanoside **8** was obtained according to the general procedure for transglycosylation by incubation of solketal in the presence of the Ara<sup>51</sup> wt. After chromatographic purification, it was isolated in 36% yield (10.5 mg). <sup>1</sup>H NMR (CD<sub>3</sub>OD):  $\delta$  4.92 (d, 1H,  $J_{1,2}$  = 1.6 Hz, H-1), 4.31-4.27 (m, 1H, CH<sub>2</sub>CHCH<sub>2</sub>), 4.05 (ddd, 1H,  $J$  = 2.4 Hz,  $J$  = 6.8 Hz,  $J$  = 8.4 Hz, O-1CH<sub>2</sub>CHCH<sub>2</sub>O), 3.99 (dd, 1H,  $J_{2,3}$  = 3.6 Hz, H-2), 3.92-3.90 (m, 1H, H-4), 3.84 (dd, 1H,  $J_{3,4}$  = 6.0 Hz, H-3), 3.78-3.74 (m, 2H, O-1CH<sub>2</sub>CH-CH<sub>2</sub>, O-1CH<sub>2</sub>), 3.71 (dd, 1H,  $J_{4,5a}$  = 5.2 Hz,  $J_{5a,5b}$  = 12 Hz, H-5a), 3.64 (dd, 1H,  $J_{4,5b}$  = 5.6 Hz, H-5b), 3.50-3.47 (m, 1H, O-1CH<sub>2</sub>), 1.38 (s, 3H, CH<sub>3</sub>), 1.32 (s, 3H, CH<sub>3</sub>). <sup>13</sup>C NMR (CD<sub>3</sub>OD):  $\delta$  109.7 (C-1), 85.7 (C-4), 83.1 (C-2), 78.8 (C-3), 75.9 (CH), 69.1 (O-1CH<sub>2</sub>CH), 67.6 (O-1CH<sub>2</sub>CHCH<sub>2</sub>), 63.0 (C-5), 27.0 (CH<sub>3</sub>), 25.6 (CH<sub>3</sub>). HRMS (ESI<sup>+</sup>): calcd for C<sub>11</sub>H<sub>20</sub>O<sub>7</sub>Na [M+Na]<sup>+</sup> m/z 287.1107; found, m/z 287.0985.

#### Acknowledgments

We are grateful to the Région Bretagne for a grant to A. P. We also thank Prof. G. J. Davies for providing the wild type and Jean-Paul Guégan (ENSCR) for recording NMR spectra.

#### References

- (1) Lombard, V.; Golaconda Ramulu, H.; Drula, E.; Coutinho, P. M.; Henrissat, B. *Nucleic Acids Res.* **2014**, *42*, D490-D495.
- (2) Armstrong, Z.; Withers, S. G. *Biopolymers* **2013**, *99*, 666-674.
- (3) Cobucci-Ponzano, B.; Moracci, M. *Nat. Prod. Rep.* **2012**, *29*, 697-709.



- (4) Brian P. Rempel, M. B. T., Don J. Mahuran, and Stephen G. Withers *Angew. Chem. Int. Ed.* **2011**, *50*, 10381-10383.
- (5) Kadokawa, J.-i. *Chem. Rev.* **2011**, *111*, 4308-4345.
- (6) Hancock, S. M.; Rich, J. R.; Caines, M. E. C.; Strynadka, N. C. J.; Withers, S. G. *Nature Chem. Biol.* **2009**, 508-514.
- (7) Faijes, M.; Planas, A. *Carbohydr. Res.* **2007**, *342*, 1581-1594.
- (8) Dureau, R.; Legentil, L.; Daniellou, R.; Ferrières, V. *J. Org. Chem.* **2012**, *77*, 1301-1307.
- (9) Lowary, T. L. *Curr. Opin. Chem. Biol.* **2003**, *7*, 749-756.
- (10) Sanchez, S.; Bamhaoud, T.; Prandi, J. *Eur. J. Org. Chem.* **2002**, 3864-3873.
- (11) Ferrières, V.; Nugier-Chauvin, C.; Legentil, L.; Tranchimand, S. In *Carbohydrate Chemistry. Chemical and Biological approaches.*; Rauter, A. P., Lindhorst, T., Queneau, Y., Eds.; 2014; Vol. 40, pp 401-417.
- (12) Teze, D.; Hendrickx, J.; Czjzek, M.; Ropartz, D.; Sanejouand, Y.-H.; Tran, V.; Tellier, C.; Dion, M. *Protein Eng. Des. Sel.* **2014**, *27*, 13-19.
- (13) Feng, H.-Y.; Drone, J.; Hoffmann, L.; Tran, V.; Tellier, C.; Rabiller, C.; Dion, M. *J. Biol. Chem.* **2005**, *280*, 37088-37097.
- (14) Koné, F. M. T.; Le Béhec, M.; Sine, J.-P.; Dion, M.; Tellier, C. *Protein Eng. Des. Sel.* **2009**, *22*, 37-44.
- (15) Suleman, M.; Gangneux, J.-P.; Legentil, L.; Belaza, S.; Cabezas, Y.; Manuela, C.; Dureau, R.; Sergent, O.; Burel, A.; Daligault, F.; Ferrières, V.; Robert-Gangneux, F. *Antimicrob. Agents Chemother.* **2014**, *58*, 2156-2166.
- (16) Legentil, L.; Audic, J.-L.; Daniellou, R.; Nugier-Chauvin, C.; Ferrières, V. *Carbohydr. Res.* **2011**, *346*, 1541-1545.
- (17) Chlubnová, I.; Filipp, D.; Spiwok, V.; Dvořáková, H.; Daniellou, R.; Nugier-Chauvin, C.; Králová, B.; Ferrières, V. *Org. Biomol. Chem.* **2010**, *8*, 2092-2102.
- (18) von Rybinski, W.; Hill, K. *Angew. Chem. Int. Ed.* **1998**, *37*, 1328-1345.

- (19) Goodby, J. W.; Haley, J. A.; MacKenzie, G.; Watson, M. A. J.; Plusquellec, D.; Ferrières, V. *J. Mater. Chem.* **1995**, *5*, 2209-2220.
- (20) Chlubnová, I.; Králová, B.; Dvořáková, H.; Hošek, P.; Spiwok, V.; Filipp, D.; Nugier-Chauvin, C.; Daniellou, R.; Ferrières, V. *Org. Biomol. Chem.* **2014**, *12*, 3080-3089.
- (21) Rémond, C.; Plantier-Royon, R.; Aubry, N.; Maes, E.; Bliard, C.; O'Donohue, M. J. *Carbohydr. Res.* **2004**, *339*, 2019-2025.
- (22) Rémond, C.; Plantier-Royon, R.; Aubry, N.; O'Donohue, M. J. *Carbohydr. Res.* **2005**, *340*, 637-644.
- (23) Rémond, C.; Ferchichi, M.; Aubry, N.; Plantier-Royon, R.; Portella, C.; O'Donohue, M. *J. Tetrahedron Lett.* **2002**, *43*, 9653-9655.
- (24) Pennec, A.; Chlubnova, I.; Daniellou, R.; Ferrières, V.; Nugier-Chauvin, C. *U.S. Provisional* **2012**, N° 61/636883.
- (25) Berlin, W.; Sauer, B. *Anal. Biochem.* **1996**, *243*, 171-175.
- (26) Finch, P.; Iskander, G. M.; Siriwardena, A. H. *Carbohydr. Res.* **1991**, *210*, 319-325.
- (27) Mizutani, K.; Kasai, R.; Nakamura, M.; Tanaka, O.; Matsuura, H. *Carbohydr. Res.* **1989**, *185*, 27-38.
- (28) Dutton, G. G. S.; Tanaka, Y.; Yates, K. *Can. J. Chem.* **1959**, *37*, 1955-1958.
- (29) Taylor, E. J.; Smith, N. L.; Turkenburg, J. P.; D'Souza, S.; Gilbert, H. J.; Davies, G. J. *Biochem. J.* **2006**, *395*, 31-37.
- (30) Bradford, M. M. *Anal. Biochem.* **1976**, *72*, 248-254.


# **Araf51 with improved transglycosylation activities: One engineered biocatalyst for one specific acceptor.**

Alizé Pennec,<sup>a,b</sup> Richard Daniellou,<sup>a,b,\*\*</sup> Pascal Loyer,<sup>b,c</sup> Caroline Nugier-Chauvin\*,<sup>a,b</sup> Vincent Ferrières\*,<sup>a,b</sup>

<sup>a</sup> Ecole Nationale Supérieure de Chimie de Rennes, CNRS, UMR 6226, 11 Allée de Beaulieu, CS 50837, 35708 Rennes Cedex 7, France

<sup>b</sup> Université européenne de Bretagne, France

<sup>c</sup> INSERM UMR 991, Hôpital Pontchaillou, 35033 Rennes Cedex, France



\*Corresponding author at: Ecole Nationale Supérieure de Chimie de Rennes, CNRS, UMR 6226, 11 Allée de Beaulieu, CS 50837, 35708 Rennes Cedex 7, France. Tel.: 33(0)2 23238066. Email address: caroline.nugier@ensc-rennes.fr

\*\* Present address: Institut de Chimie Organique et Analytique (ICOA), UMR CNRS 7311, Université d'Orléans, BP 6759, Rue de Chartres, 45067 Orléans Cedex 2, France

**Ara51 with improved transglycosylation activities: One engineered biocatalyst for one specific acceptor.**

Alizé Pennec,<sup>a,b</sup> Richard Daniellou,<sup>a,b,††</sup> Pascal Loyer,<sup>b,c</sup> Caroline Nugier-Chauvin\*,<sup>a,b</sup> Vincent Ferrières\*,<sup>a,b</sup>

<sup>a</sup> Ecole Nationale Supérieure de Chimie de Rennes, CNRS, UMR 6226, 11 Allée de Beaulieu, CS 50837, 35708 Rennes Cedex 7, France

<sup>b</sup> Université européenne de Bretagne, France

<sup>c</sup> INSERM UMR 991, Hôpital Pontchaillou, 35033 Rennes Cedex, France

**Highlights**

A random mutagenesis of Ara51 affords improved biocatalysts for transglycosylation.  
Five efficient mutated enzymes for the synthesis of alkyl furanosides.  
Each selected mutant is specific for one alcohol acceptor.

---

\*Corresponding author at: Ecole Nationale Supérieure de Chimie de Rennes, CNRS, UMR 6226, 11 Allée de Beaulieu, CS 50837, 35708 Rennes Cedex 7, France. Tel.: 33(0)2 23238066. Email address: caroline.nugier@ensc-rennes.fr

†† Present address: Institut de Chimie Organique et Analytique (ICOA), UMR CNRS 7311, Université d'Orléans, BP 6759, Rue de Chartres, 45067 Orléans Cedex 2, France